Ignite Creation Date:
2024-10-25 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06575049
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-26
Brief Title:
Seroma and Hematoma Rates MAXIGESIC IV vs Ketorolac in Breast Cancer Surgery
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Comparative Analysis of Seroma and Hematoma Rates MAXIGESIC vs Ketorolac in Breast Cancer Surgery Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators aim to compare the incidence rates of seroma fluid collection and hematoma blood clot following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug NSAID Ketorolac and MAXIGESIC The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None